<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> is of prognostic importance not only in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> but also in malignant <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We measured levels of vascular endothelial growth factor (VEGF), angiogenin (ANG), and basic fibroblast growth factor (bFGF) in peripheral blood samples from 65 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), from 25 patients with de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and from 50 healthy donors </plain></SENT>
<SENT sid="2" pm="."><plain>In matched samples, VEGF levels in serum were substantially higher than VEGF levels in plasma (380.7 +/- 56 pg/ml vs. 45.3 +/- 4.5 pg/ml, mean +/- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>, p &lt; 0.001), whereas serum and plasma levels of ANG were comparable and significantly correlated (r = 0.8; p &lt; 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>Compared to <z:mpath ids='MPATH_458'>normal</z:mpath> controls (1.3 +/- 0.09 pg), serum levels of VEGF corrected for the peripheral blood platelet count (VEGF/10(6) platelets, VEGF(PLT)) were elevated in patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA; 3.1 +/- 0.8 pg, p &lt; 0.01), and reached maximal values in patients with advanced stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) (3.5 +/- 0.6 pg, p &lt; 0.001), de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (3.6 +/- 1.1 pg, p &lt; 0.05), and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>; 3.7 +/- 0.9 pg; p &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>Levels of soluble ANG were elevated in RA (351 +/- 25.7 ng/ml, p &lt; 0.001), in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t (402 +/- 17.9 ng/ml; p &lt; 0.001), in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> (413.8 +/- 29.5 ng/ml; p &lt; 0.001), and in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (305.1 +/- 17.1 ng/ml; p &lt; 0.01, controls 255.4 +/- 8.1 ng/ml) </plain></SENT>
<SENT sid="5" pm="."><plain>Serum bFGF was neither elevated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> nor in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggest that VEGF(PLT) is a marker of disease progression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, we show for the first time that elevated blood levels of ANG can be found in patients with <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e>, suggesting a role of ANG in the pathogenesis of these diseases </plain></SENT>
</text></document>